HC Wainwright & Co. Reiterates Buy on NovaBridge Biosciences, Maintains $9 Price Target
HC Wainwright & Co. analyst Andres Y. Maldonado reiterates NovaBridge Biosciences (NASDAQ:NBP) with a Buy and maintains $9 price target.
Stocks · News reference
NovaBridge Names Srishti Gupta CEO As Sean Fu Steps Down
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
NovaBridge Biosciences H1 EPS $(0.33) Misses $(0.14) Estimate
NovaBridge Biosciences to Hold Annual General Meeting on September 8, 2026
NovaBridge Biosciences announced its annual general meeting of shareholders will be held on September 8, 2026, at its Shanghai office. The company, a clinical-stage biopharmaceutical firm, is advancing innovative medicines including givastomig for gastric cancer and VIS-101 for retinal vascular diseases. Shareholders of record as of July 27, 2026, are entitled to attend and vote.